Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT).
John F. DiPersio(Washington University in St. Louis), Guenther Koehne(Baptist Hospital of Miami), Brenda Cooper(University Hospitals Cleveland Medical Center), Divya Koura(University of California San Diego), Nirali N. Shah(National Institutes of Health), Hyung C. Suh(Science Applications International Corporation (United States)), Glen Raffel(University of Massachusetts Chan Medical School), Kyle Breitschwerdt, Michael R. Loken(Unknown), Sritama Nath(University of North Carolina at Charlotte), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Roni Tamari(Memorial Sloan Kettering Cancer Center), Markus Y. Mapara(Sheba Medical Center), Léa Bernard(Hôpital Maisonneuve-Rosemont), Roland B. Walter(Rafael Advanced Defense Systems (Israel))
Cited by 7
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
Three-dimensional culture systems in cancer research: Focus on tumor spheroid model
|Pharmacology & Therapeutics|2016|921
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse
|Journal of Clinical Oncology|2001|898